Here, recent advances in microscale peptide chromatography are applied to HCP analysis. The novel charge-surface-modified C18 material, known as CSH C18, which can produce high peptide peak capacities even at high mass loads, is used in the format of a 15K psi capable 300 μm I.D. column along with an ACQUITY UPLC M-Class based 2D-RP/RP system and SYNAPT HDMSE detection to provide a robust analytical workflow for the identification of low concentrations of HCP impurities at single digit PPM levels (parts per million, or ng/mg).
Microscale LC-MS techniques are widely used by analytical laboratories for high sensitivity applications. Since improvements in peak capacity enhance the ability to resolve and detect trace-level components, high peak capacity separations are extremely advantageous in these examples of narrow I.D. (100–1000 μm) column chromatography, particularly during complex sample analyses, such as the identification of host cell protein (HCP) impurities in biotherapeutic products.1-3 Here, recent advances in microscale peptide chromatography are applied to HCP analysis. The novel charge-surface-modified C18 material, known as CSH C18, which can produce high peptide peak capacities even at high mass loads, is used in the format of a 15K psi capable 300 μm I.D. column along with an ACQUITY UPLC M-Class based 2D-RP/RP system and SYNAPT HDMSE detection to provide a robust analytical workflow for the identification of low concentrations of HCP impurities at single digit PPM levels (parts per million, or ng/mg).
An IgG1K mAb (2.5 mg) was denatured, reduced, alkylated, and digested with trypsin in the presence of ~0.1% (w/v) RapiGest and 50 mM ammonium bicarbonate using reagents and conditions similar to those previously published.1 The resulting 2.5 μg/μL tryptic digest was prepared such that it was titrated to a basic pH (~pH 10) and spiked with tryptic peptides from rabbit glycogen phosphorylase at a concentration of 4 fmol/μL.
LC conditions |
|
LC system: |
ACQUITY UPLC M-Class 2D System with a CH-A 20 cm Column Heater (p/n 186015042) |
Sample temp.: |
5 °C |
1st dimension mobile phase A (also weak needle wash): |
20 mM ammonium formate, pH 10 |
1st dimension mobile phase B (also strong needle wash): |
Acetonitrile |
ASM dilution mobile phase: |
0.1% TFA (v/v), water (ASM Pump A) |
2nd dimension mobile phase A: |
0.1% formic acid (v/v), water |
2nd dimension mobile phase B: |
0.1% formic acid (v/v), acetonitrile |
1st dimension column temp.: |
Ambient |
Trapping column temp.: |
Ambient (when configured for conventional silica C18 analytical columns), 60 °C (for CSH C18 analytical columns) |
Analytical column temp.: |
45 °C (conventional silica C18), 40 °C (CSH C18) |
Injection volume: |
80 μL (0.2 mg mass load) or 4 x 100 μL (1 mg mass load) |
Sample loop volume: |
250 μL (custom replacement of the standard 100 μL sample loop) |
Run time per replicate analysis: |
10 x [20 min 1st dimension step gradient and trapping method + 45 min 2nd dimension run] |
1st dimension column: |
XBridge Peptide BEH C18, 300Å, 5 μm, 1.0 x 50 mm (p/n 186003615) [Note: XBridge Peptide BEH C18, 130Å, 5 μm, 1.0 x 50 mm (p/n 186003571) can also be used. However, 1st dimension chromatographic selectivity may change.] |
Analytical column: |
Conventional silica C18, 100Å, 1.7 μm, 300 μm x 150 mm, or ACQUITY UPLC M-Class CSH C18, 130Å, 1.7 μm, 300 μm x 150 mm (p/n 186007563) |
Trapping column: |
ACQUITY UPLC M-Class Symmetry C18, 2D HCP Trap, 100Å, 5 μm, 300 μm x 25 mm (p/n 186007499) |
Vials: |
LCGC Certified Clear Glass 12 x 32 mm Screw Neck Qsert Vial (p/n 186001126C) |
2nd dimension pump
*All curve styles are linear.
Time |
Flow (μL/min) |
%B |
---|---|---|
0 |
8.0 |
5% (2% or CSH C18) |
Time |
Flow (μL/min) |
%B |
---|---|---|
0 |
8.0 |
5% (2% or CSH C18) |
30 |
8.0 |
40% (37% for CSH C18) |
32 |
8.0 |
85 |
34 |
8.0 |
85 |
36 |
8.0 |
5% (2% for CSH C18) |
45 |
8.0 |
5% (2% for CSH C18) |
Time |
Flow (μL/min) |
%B |
---|---|---|
0 |
8 |
2 |
30 |
8 |
37 |
32 |
8 |
85 |
34 |
8 |
85 |
36 |
8 |
2 |
45 |
8 |
2 |
Time |
Flow (μL/min) |
%B |
---|---|---|
0.0 |
10 |
3 |
0.2 |
10 |
3 |
0.5 |
10 |
X |
15.5 |
10 |
X |
16.0 |
10 |
3 |
20.0 |
10 |
3 |
Time |
Flow (μL/min) |
%B |
---|---|---|
0 |
10 |
3 |
X = 10.7 (1st Fraction), 12.4% (2nd Fraction),
14.0% (3rd Fraction), 15.4% (4th Fraction),
16.7% (5th Fraction), 18.6% (6th Fraction),
20.4% (7th Fraction), 25.0% (8th Fraction),
30.0% (9th Fraction), 50.0% (10th Fraction)
ASM pump: The A side was held at 100 μL/min during both 2nd dimension analytical gradients and 1st dimension trapping gradients. The B-side was held at 5 μL/min (LockSpray).
MS system: |
SYNAPT G2-S (with a Microscale ESI Probe (p/n 186007529) |
Ionization mode: |
ESI+ |
Analyzer mode: |
Resolution (~20 K) |
Capillary voltage: |
3.0 kV |
Cone voltage: |
30 V |
Source offset: |
50 V |
Source temp.: |
100 °C |
Desolvation temp.: |
250 °C |
Desolvation gas flow: |
800 L/hr |
Calibration: |
NaI, 2 μg/μL from 100–2000 m/z |
Lockspray (ASM B-side): |
500 fmol/μL Human Glufibrinopeptide B in 0.1% (v/v) formic acid, 70:30 water/acetonitrile every 4 min |
Acquisition: |
50–1990 m/z, 0.3 sec scan rate |
Trap collision energy: |
5 V |
Transfer collision energy: |
4 V |
Trap collision energy: |
20–45 V ramp |
Transfer collision energy: |
10 V |
IMS wave velocity: 600 m/s
Trap collision energy: |
4 V |
Transfer collision energy: |
2 V |
Trap collision energy: |
4 V |
Transfer collision energy: |
20–45 V |
Data management: |
MassLynx Software (v4.1) ProteinLynx Global SERVER/PLGS (v3.0.1) |
Target database: mAb light and heavy chain sequences + UniProt Mus musculus reference proteome [1185] + calibrant protein (rabbit glycogen phosphorylase) sequence [UniProt P00489] Decoy Database (searched along with target database): 1x randomized target database
Low energy threshold: |
150 counts |
Elevated energy threshold: |
30 counts |
Intensity threshold: |
1500 counts |
Default settings except for the following |
|
Peptide tolerance: |
15 ppm |
Fragment tolerance: |
20 ppm |
False discovery rate: |
15% (Note that the protein match criteria listed below compensated for this low fidelity matching.) |
Protein PLGS score >270
Supported by ≥3 unique peptide hits
Protein identified in at least 2 out of 3 replicate analyses
CSH C18, with its positive surface potential at an acidic pH, minimizes undesired secondary interactions, exhibits enhanced loadability, and thereby minimizes peak broadening at high mass loads.4 Such chromatographic performance is well suited to the analysis of HCPs, where there is a need to identify low-ppm impurities in the presence of highly abundant product-derived peptides that readily cause ion suppression and spectral crowding if co-elution occurs. It has previously been demonstrated that two-dimensional (high pH/low pH) RP/RP separations can be used to obtain high peak capacity peptide separations and to identify HCP impurities.1,5 Indeed, such chromatography operated at near 10K psi with an ACQUITY UPLC M-Class System and 300 μm I.D. sub-2-μm, silica-based C18 analytical column produces a theoretical peak capacity (half-height) of 2535 when a test mixture is analyzed at low mass loads.6 In practice, however, this peak capacity is substantially compromised when analyzing the mass loads required to characterize HCPs. Interestingly, the use of CSH C18 in the 2nd dimension of such a 2D-RP/RP system has been found to minimize the peak broadening observed during HCP analyses. CSH C18 thus enables even higher mass loads to be analyzed without significant losses in peak capacity, which assists in detection of impurities at increasingly lower abundances.
For this reason, the combination of UPLC 2D-RP/RP with a 300 μm I.D. CSH C18 column is presented for improved HCP analysis. Figure 1 shows a schematic of this apparatus, in which an ACQUITY UPLC M-Class System is outfitted with an ACQUITY UPLC CH-A Column Heater to allow for differential heating of trapping and analytical columns. Dual zone heating can be essential to optimizing trap-elute separations, such as the second dimension segment of this 2D-RP/RP system. Here, a Symmetry C18 trapping column is maintained at 60 °C to facilitate optimal refocusing on the CSH C18 2nd dimension analytical column (see Reference 7 for more information on differential column heating).7
The capabilities of this system are unprecedented in terms of both peak capacity and loadability. Figure 2 shows base peak intensity (BPI) chromatograms resulting from a 10-step 2D-RP/RP separation of an inordinately high, 1 mg mass load of a trypsin digested monoclonal antibody (mAb). In comparison to an analogous 2D separation using conventional (not charge surface modified) silica C18 for the 2nd dimension, CSH C18 yields 2nd dimension separations with distinctively sharper peaks for high abundance species, thereby allowing for improved detection of low abundance species. Moreover, these pronounced performance gains are obtainable even at mass loads higher than those typically explored with conventional silica C18. The comparison of Figure 2, in fact, shows results from using conventional silica C18 to study 0.2 mg of a mAb digest versus using CSH C18 to study that same sample at a 1 mg mass load. Figure 3 underscores the described separation capabilities of CSH C18, as it displays a single fraction from these two different 2D analyses, where again it is apparent that CSH C18 better minimizes the peak broadening inherent in high mass load/overloaded peptide chromatography.
The improved resolution in the 2nd dimension afforded by CSH C18 is useful to HCP analysis, but perhaps more so is the fact that it is possible with CSH C18 to load at least 5 times more sample. This has the effect to shift the dynamic range of the analysis to encompass lower limits of detection. In addition, the analysis of increased mass loads pairs well with ion mobility enabled MS detection, since ion mobility operation (e.g. HDMSE) generally yields slightly lower ion counts versus MS detection without an ion mobility separation (e.g. MSE). Despite the decrease in ion intensity, ion mobility enabled MS detection is of significant value to HCP analysis itself, as it reduces spectral crowding of precursor and fragment ion spectra. In this way, ion mobility assisted data independent analyses, like HDMSE, are effective in extracting more information from an analysis, since spectral matching can be performed with greater confidence and precursor mass information can be better correlated to fragment ion spectra. (For a review of data independent analyses [MSE] and ion mobility enabled data independent analyses [HDMSE], please refer to Reference 8).8
The value of these above mentioned technological advances was tested. Specifically, the results from 2D-RP/RP with conventional silica C18 combined with MSE to analyze 0.2 mg of an mAb digest were compared with those from 2D-RP/RP with CSH C18 combined with HDMSE to analyze 1.0 mg of an mAb digest. Mass spectral data obtained in either case were searched against the sequence of the mAb, trypsin, and the host cell proteome with ProteinLynx Global SERVER (PLGS), a database driven search algorithm for spectral matching and protein identification. The mAb sample analyzed in this study was an IgG1K expressed from a murine cell line; consequently, the Mus musculus reference proteome was downloaded from UniProt and used to identify peptides and thus protein impurities from the host cell line. Guidelines similar to those established previously were followed to ensure high confidence identifications were obtained from PLGS processing.2-3 Most notably, it was required that a host cell protein be identified in at least two out of the three replicate analyses that were performed. The resulting number of host cell proteins identified by the two methods being compared is shown in Figure 4A. The 2D-RP/RP with conventional silica C18 combined with MSE to analyze 0.2 mg of an mAb digest produced 5 HCP identifications while the 2D-RP/RP with CSH C18 combined with HDMSE to analyze 1.0 mg of an mAb digest yielded 14 HCP identifications. The noted advances in LC-MS technology therefore facilitated obtaining almost 3 times more information about the HCP profile of this mAb sample.
More interesting is the type of information provided by these recent advances. HCP analysis by these techniques can be qualitative in the sense that a list of protein impurities can be obtained. However, it can likewise be made quantitative through what is referred to as “Hi3” quantitation.9-10 In this analysis, the digest of a protein, for instance trypsin digest, rabbit glycogen phosphorylase, is spiked into the digested sample at a concentration that is predicted to be similar to the target analytes. For this analysis, that would be a 20–200 ppm concentration. Intensities observed for the top 3 most intense precursors (the so-called “Hi3”) can then be used to develop a single point calibration for determining on-column loads. Using the intensities of the target analyte’s top 3 most intense precursors, the analyst can thereby obtain an estimated concentration for an identified HCP. Previous microscale LC-based HCP analyses, typified by the results obtained with a conventional silica C18 2nd dimension and MSE detection, exhibit limits of detection of approximately 20 ppm.1 The combined use of CSH C18 for the 2nd dimension, 5x higher mass loads, and HDMSE has made a significant improvement to this capability where 7 of the 14 HCPs identified by Hi3 quantitation are estimated to be present in the sample at concentrations below 20 ppm (Figure 4B). The two lowest abundance HCPs identified are actually estimated to be present at 2 and 6 ppm concentrations, respectively. In summary, marked improvements in both the qualitative and quantitative results of an HCP analysis by LC-MS are achieved with these recent examples of method development.
Recent advances in microscale peptide chromatography have been applied to HCP analysis. The novel charge-surface-modified C18 material, known as CSH C18, has been used in the format of a 15K psi capable 300 μm I.D. column along with an ACQUITY UPLC M-Class based 2D-RP/RP system and SYNAPT HDMSE detection to provide a robust analysis workflow for the identification of low-ppm HCP impurities. The use of CSH C18 in the 2nd dimension of such a 2D-RP/RP system has been found to minimize the peak broadening of the abundant peptides observed during HCP analyses, enabling inordinately high mass loads to be analyzed and the dynamic range of an analysis to be shifted to encompass lower limits of detection. These high mass load analyses pair well with ion mobility enabled MS detection (e.g. HDMSE), which itself reduces spectral crowding of precursor and fragment ion spectra and enables improved correlation between precursor and fragment ion spectra. In combination, these recent advances facilitate HCP analysis, making it possible to profile protein impurities down to low ppm concentrations. That these recent advances have been developed around rugged, user-friendly 15K psi microscale LC make this a very promising strategy for investigating HCPs in biotherapeutics as well as low abundance protein species in proteomic-type samples.
720005076, June 2014